Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

ClinicalTrials.gov ID: NCT03921879

Public ClinicalTrials.gov record NCT03921879. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 12:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of OT-82 in Patients With Relapsed or Refractory Lymphoma

Study identification

NCT ID: NCT03921879
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Oncotartis, Inc.; Industry
Enrollment: 50 participants

Conditions and interventions

Conditions

Interventions

OT-82 Dose Escalation Drug
OT-82 Dose Expansion Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 28, 2019
Primary completion: Mar 31, 2021
Completion: May 31, 2021
Last update posted: Oct 22, 2020

2019 – 2021

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294	Recruiting
City of Hope National Medical Center	Duarte	California	91010	Recruiting
Sylvester Comprehensive Cancer Center	Miami	Florida	33136	Recruiting
University of Michigan	Ann Arbor	Michigan	48109	Recruiting
Roswell Park Cancer Institute	Buffalo	New York	14263	Recruiting
University Hospitals Seidman Cancer Center	Cleveland	Ohio	44106	Recruiting
Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	Recruiting
Thomas Jefferson University Hospital	Philadelphia	Pennsylvania	19107	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03921879, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 22, 2020 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03921879 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →